Retatrutide and fatty liver (MASLD/MASH) in the US: what trials measure and what to track

Short answer

Retatrutide (LY3437943) is a once-weekly triple incretin/glucagon receptor agonist (GIP + GLP‑1 + glucagon) being studied for obesity and metabolic disease, with a dedicated MASLD (fatty liver) substudy published in 2024. In that substudy, the key outcome was change in liver fat measured by MRI‑PDFF, plus supportive changes in ALT/AST and noninvasive fibrosis markers.

References

• MASLD substudy (PMC): https://pmc.ncbi.nlm.nih.gov/articles/PMC11271400/
• NIDDK diagnosis: https://www.niddk.nih.gov/health-information/liver-disease/nafld-nash/diagnosis
• ClinicalTrials.gov: https://clinicaltrials.gov/study/NCT04881760